Sanofi India (BOM:500674) Accounts Payable: ₹2,740 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,275.70
GF Value ₹4,396.93
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Accounts Payable?

Sanofi India BOM:500674 -2.17% 77 Accounts Payable is ₹2,740 Mil as of Jun. 2026. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,396.93 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sanofi India's Accounts Payable for the quarter that ended in Jun. 2026 was ₹2,740 Mil.

Sanofi India's quarterly Accounts Payable declined from Dec. 2025 (₹1,940 Mil) to Mar. 2026 (₹0 Mil) but then increased from Mar. 2026 (₹0 Mil) to Jun. 2026 (₹2,740 Mil).

Sanofi India's annual Accounts Payable increased from Dec. 2023 (₹2,915 Mil) to Dec. 2024 (₹4,063 Mil) but then declined from Dec. 2024 (₹4,063 Mil) to Dec. 2025 (₹1,940 Mil).

Sanofi India Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sanofi India's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi India Accounts Payable Chart

Sanofi India Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,767.00 3,564.00 2,915.00 4,063.00 1,940.00

Sanofi India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,445.00 0.00 1,940.00 0.00 2,740.00
BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi India Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹2,740 Mil mean?
Sanofi India (BOM:500674) has a Accounts Payable of ₹2,740 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sanofi India and its competitors.
Is Sanofi India's Accounts Payable too high?
Sanofi India's current Accounts Payable is ₹2,740 Mil. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Accounts Payable compare to LLY and JNJ?
Sanofi India's Accounts Payable of ₹2,740 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sanofi India and its competitors. Sanofi India's current Accounts Payable is ₹2,740 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,396.93, compared to a current price of ₹3,275.70 — trading 25.5% below its estimated fair value. The current Accounts Payable is ₹2,740 Mil. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Accounts Payable is ₹2,740 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,275.70 is trading 25.5% below its estimated GF Value™ of ₹4,396.93. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Accounts Payable: ₹2,740 Mil
  • GF Value™: ₹4,396.93 vs. price of ₹3,275.70 (25.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,275.70
Price
₹4,396.93
GF Value